Tuesday, April 18, 2017

Hidden studies & cancer breakthroughs

Dr. John Beard who first discovered that the trophoblast cells of the placenta mirrored the undifferentiated, primitive cancer cells, extensively studied the clinical use of trypsin and amylase in cancer treatment.  Trypsin was named by German scientist, W. Kuhne in 1867.  In Greek trypsin means "I wear away" to demonstrate the intense metabolic activity of this enzyme.  Trypsin was first used in treatment of diphtheria.  Diphtheria bacteria produces a thick membrane in the throat that could lead to suffocation.  Injectable trypsin digested this membrane in animals exposed to the bacteria.

Dr. John Beard explored the injectable form of pancreatic enzymes and its clinical use in cancer treatments. The therapeutic use of pancreatic enzymes was a delicate scientific process because trypsin was highly active to the point of self-destruction if extraction methods were not done with exacting precision.

In fact, because of the need for precise methods, Beard became involved in the manufacturing process of the enzymes.  He assisted Fairchild in the process necessary to extract the highest amount of pancreatic enzymes without the loss of enzymes from self-combustion.  When Beard believed that they developed the highest potency injectable enzyme therapy, he began to experiment with animals.

The Jensen mouse tumors were clinically sound and available for use in cancer research in the early 1900s.  Beard began experimenting with using injectable trypsin in isolation and in combination with amylase.  When Beard used trypsin in isolation with too high of a dose in animals with cancer, he would see the animals die quickly.  He postulated that the animals were dying because of the high amounts of toxins being released while the tumor was being digested by the enzymes.

Thus, Beard began to experiment with trypsin injections followed by injections of amylase for several days.  He found the animals thriving in their recovery as amylase helped to clear the excess toxins from the destruction that trypsin had upon the tumor mass.

In 1906, The British Medical Journal published the first successes with enzyme therapy in the Jensen mouse tumor models.  Beard attracted a lot of positive and negative reactions from his work.  In fact, he had doctors critiquing every detail of his work down to questioning whether the mice had cancer in the first place.  They were incredulous that Beard would have discovered a cancer cure. 

However, despite the attacks, Beard continued forward to research his therapy on human patients.  In the first human trial, Beard used everything he learned from study with mice on human patients that failed conventional treatments.  He used 1,000 units of trypsin and 2,000 units of amylase in the injectable form daily. Physicians who used the proper dosing and proper approach reported great results.

Because of Beard's success, drug companies between 1906-1910 created and marketed their own enzyme preparations in a very sloppy, unscientific manner. Physicians using preparations outside of the Fairchild preparations influenced by Beard himself, found little success.  Some physicians used the Fairchild preparations with the wrong dosage or without amylase.

The cancer world hotly debated Beard's work and with the new flurry of activity surrounding radiation therapy, many physicians and researchers abandoned enzyme therapy without doing due diligence and with no regard to Beard's lifelong landmark discoveries.  In 1969, The U.S. Food and Drug Administration issued an order to outlaw the manufacturing and clinical usage of injectable pancreatic enzymes.  It would seem that Beard's work would die without advantage in clinical use for desperate cancer patients.  However, the good news is that injectable formula's of pancreatic enzymes are now on the rise, especially in Germany.

1.  Gonzalez, Nicholas J.  Nutrition And The Autonomic Nervous System.  The Scientific Foundations of The Gonzalez Protocol.